Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Figitumumab [USAN:INN]
RN: 943453-46-1
UNII: VE267FC2UB

Notes

  • An anti-insulin-like growth factor-I receptor monoclonal antibody in Phase I clinical trials.
  • An anti-insulin-like growth factor-I receptor monoclonal antibody in Phase I clinical trials.

    NCI: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival. (NCI Thesaurus)

Molecular Formula

  • Unspecified
 

Classification Code

  • Treatment of Cancer
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Figitumumab [USAN:INN]

Synonyms

  • CP 751871
  • CP-751,871
  • CP-751871
  • Figitumumab
  • UNII-VE267FC2UB

Systematic Name

  • Immunoglobulin G2, anti-(human insulin-like growth factor I receptor)(human monoclonal CP-751,871 clone 2.13.2 heavy chain) disulfide with human monoclonal CP-751,871 clone 2.13.2 light chain, dimer

Registry Numbers

CAS Registry Number

  • 943453-46-1

FDA UNII

  • VE267FC2UB

System Generated Number

  • 0943453461